Accessibility: Skip TopNav
Figure 1. 2nd MSA patient on nasal foralumab
Significant reduction in basal ganglia and thalamic uptake following nasal foralumab
Format
PNG
Source
Tiziana Life Sciences Ltd.
Downloads
Original
Large
Medium
Small